|
1.
|
Agostinis P, Berg K, Cengel KA, Foster TH,
Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel
D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC and
Golab J: Photodynamic therapy of cancer: an update. CA Cancer J
Clin. 61:250–281. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Wei G, Rafiyath S and Liu D: First-line
treatment for chronic myeloid leukemia: dasatinib, nilotinib, or
imatinib. J Hematol Oncol. 3:472010. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Brooks HD, Glisson BS, Bekele BN, Johnson
FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran
HT and Papadimitrakopoulou VA: Phase 2 study of dasatinib in the
treatment of head and neck squamous cell carcinoma. Cancer.
117:2112–2119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kopetz S, Lesslie DP, Dallas NA, Park SI,
Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J
and Gallick GE: Synergistic activity of the SRC family kinase
inhibitor dasatinib and oxaliplatin in colon carcinoma cells is
mediated by oxidative stress. Cancer Res. 69:3842–3849. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Pichot CS, Hartig SM, Xia L, Arvanitis C,
Monisvais D, Lee FY, Frost JA and Corey SJ: Dasatinib synergizes
with doxorubicin to block growth, migration, and invasion of breast
cancer cells. Br J Cancer. 101:38–47. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Haura EB, Tanvetyanon T, Chiappori A,
Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L,
Neuger A, Song L, Rawal B, Schell MJ and Bepler G: Phase I/II study
of the Src inhibitor dasatinib in combination with erlotinib in
advanced non-small-cell lung cancer. J Clin Oncol. 28:1387–1394.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Raju U, Riesterer O, Wang ZQ, Molkentine
DP, Molkentine JM, Johnson FM, Glisson B, Milas L and Ang KK:
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity
by interfering with nuclear localization of epidermal growth factor
receptor and by blocking DNA repair pathways. Radiother Oncol.
105:241–249. 2012. View Article : Google Scholar
|
|
8.
|
Adan-Gokbulut A, Kartal-Yandim M, Iskender
G and Baran Y: Novel agents targeting bioactive sphingolipids for
the treatment of cancer. Curr Med Chem. 20:108–122. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Hannun YA and Obeid LM: Many ceramides. J
Biol Chem. 286:27855–27862. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Saddoughi SA and Ogretmen B: Diverse
functions of ceramide in cancer cell death and proliferation. Adv
Cancer Res. 117:37–58. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Separovic D, Breen P, Joseph N, Bielawski
J, Pierce JS, Van Buren E and Gudz TI: Ceramide synthase 6
knockdown suppresses apoptosis after photodynamic therapy in human
head and neck squamous carcinoma cells. Anticancer Res. 32:753–760.
2012.PubMed/NCBI
|
|
12.
|
Separovic D, Breen P, Joseph N, Bielawski
J, Pierce JS, Van Buren E and Gudz TI: siRNA-mediated
down-regulation of ceramide synthase 1 leads to apoptotic
resistance in human head and neck squamous carcinoma cells after
photodynamic therapy. Anticancer Res. 32:2479–2485. 2012.
|
|
13.
|
Gencer EB, Ural AU, Avcu F and Baran Y: A
novel mechanism of dasatinib-induced apoptosis in chronic myeloid
leukemia; ceramide synthase and ceramide clearance genes. Ann
Hematol. 90:1265–1275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Khurana D, Martin EA, Kasperbauer JL,
O’Malley BW Jr, Salomao DR, Chen L and Strome SE: Characterization
of a spontaneously arising murine squamous cell carcinoma (SCC VII)
as a prerequisite for head and neck cancer immunotherapy. Head
Neck. 23:899–906. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Suit HD, Sedlacek RS, Silver G and
Dosoretz D: Pentobarbital anesthesia and the response of tumor and
normal tissue in the C3Hf/sed mouse to radiation. Radiat Res.
104:47–65. 1985. View
Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Separovic D, Semaan L, Tarca AL, Awad
Maitah MY, Hanada K, Bielawski J, Villani M and Luberto C:
Suppression of sphingomyelin synthase 1 by small interference RNA
is associated with enhanced ceramide production and apoptosis after
photodamage. Exp Cell Res. 314:1860–1868. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Bai A, Szulc ZM, Bielawski J, Mayroo N,
Liu X, Norris J, Hannun YA and Bielawska A: Synthesis and
bioevaluation of omega-N-amino analogs of B13. Bioorg Med Chem.
17:1840–1848. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Dolgachev V, Farooqui MS, Kulaeva OI,
Tainsky MA, Nagy B, Hanada K and Separovic D: De novo ceramide
accumulation due to inhibition of its conversion to complex
sphingolipids in apoptotic photosensitized cells. J Biol Chem.
279:23238–23249. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Dolgachev V, Nagy B, Taffe B, Hanada K and
Separovic D: Reactive oxygen species generation is independent of
de novo sphingolipids in apoptotic photosensitized cells. Exp Cell
Res. 288:425–436. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Separovic D, Saad ZH, Edwin EA, Bielawski
J, Pierce JS, Van Buren E and Bielawska A: C16-ceramide analog
combined with Pc 4 photodynamic therapy evokes enhanced total
ceramide accumulation, promotion of DEVDase activation in the
absence of apoptosis, and augmented overall cell killing. J Lipids.
2011:1–9. 2011. View Article : Google Scholar
|
|
21.
|
Separovic D, Mann KJ and Oleinick NL:
Association of ceramide accumulation with photodynamic
treatment-induced cell death. Photochem Photobiol. 68:101–109.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Agarwal ML, Clay ME, Harvey EJ, Evans HH,
Antunez AR and Oleinick NL: Photodynamic therapy induces rapid cell
death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res.
51:5993–5996. 1991.PubMed/NCBI
|
|
23.
|
Wispriyono B, Schmelz E, Pelayo H, Hanada
K and Separovic D: A role for the de novo sphingolipids in
apoptosis of photosensitized cells. Exp Cell Res. 279:153–165.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Nam S, Williams A, Vultur A, List A,
Bhalla K, Smith D, Lee FY and Jove R: Dasatinib (BMS-354825)
inhibits Stat5 signaling associated with apoptosis in chronic
myelogenous leukemia cells. Mol Cancer Ther. 6:1400–1405. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Lin YC, Wu MH, Wei TT, Chuang SH, Chen KF,
Cheng AL and Chen CC: Degradation of epidermal growth factor
receptor mediates dasatinib-induced apoptosis in head and neck
squamous cell carcinoma cells. Neoplasia. 14:463–475.
2012.PubMed/NCBI
|
|
26.
|
Xue T, Luo P, Zhu H, Zhao Y, Wu H, Gai R,
Wu Y, Yang B, Yang X and He Q: Oxidative stress is involved in
Dasatinib-induced apoptosis in rat primary hepatocytes. Toxicol
Appl Pharmacol. 261:280–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Rodriguez-Enfedaque A, Delmas E, Guillaume
A, Gaumer S, Mignotte B, Vayssiere JL and Renaud F: zVAD-fmk
upregulates caspase-9 cleavage and activity in etoposide-induced
cell death of mouse embryonic fibroblasts. Biochim Biophys Acta.
1823:1343–1352. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Mahdy AE, Cheng JC, Li J, Elojeimy S,
Meacham WD, Turner LS, Bai A, Gault CR, McPherson AS, Garcia N,
Beckham TH, Saad A, Bielawska A, Bielawski J, Hannun YA, Keane TE,
Taha MI, Hammouda HM, Norris JS and Liu X: Acid ceramidase
upregulation in prostate cancer cells confers resistance to
radiation: AC inhibition, a potential radiosensitizer. Mol Ther.
17:430–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Nagy B, Chiu S-M and Separovic D:
Fumonisin B1 does not prevent apoptosis in A431 human epidermoid
carcinoma cells after photosensitization with phthalocyanine 4. J
Photochem Photobiol B. 57:132–141. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Xue LY, Chiu SM and Oleinick NL:
Photodynamic therapy-induced death of MCF-7 human breast cancer
cells: a role for caspase-3 in the late steps of apoptosis but not
for the critical lethal event. Exp Cell Res. 263:145–155. 2001.
View Article : Google Scholar
|
|
31.
|
Separovic D, Joseph N, Breen P, Bielawski
J, Pierce JS, van Buren E, Bhatti G, Saad ZH, Bai A and Bielawska
A: Combining anticancer agents photodynamic therapy and LCL85 leads
to distinct changes in the sphingolipid profile, autophagy,
caspase-3 activation in the absence of cell death, and long-term
sensitization. Biochem Biophys Res Commun. 409:372–377. 2011.
View Article : Google Scholar
|
|
32.
|
Min J, Mesika A, Sivaguru M, Van Veldhoven
PP, Alexander H, Futerman AH and Alexander S: (Dihydro)ceramide
synthase 1 regulated sensitivity to cisplatin is associated with
the activation of p38 mitogen-activated protein kinase and is
abrogated by sphingosine kinase 1. Mol Cancer Res. 5:801–812. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Dumka D, Puri P, Carayol N, Lumby C,
Balachandran H, Schuster K, Verma AK, Terada LS, Platanias LC and
Parmar S: Activation of the p38 Map kinase pathway is essential for
the antileukemic effects of dasatinib. Leuk Lymphoma. 50:2017–2029.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Whitacre CM, Feyes DK, Satoh T, Grossmann
J, Mulvihill JW, Mukhtar H and Oleinick NL: Photodynamic therapy
with the phthalocyanine photosensitizer Pc 4 of SW480 human colon
cancer xenografts in athymic mice. Clin Cancer Res. 6:2021–2027.
2000.PubMed/NCBI
|
|
35.
|
Koybasi S, Senkal CE, Sundararaj K,
Spassieva S, Bielawski J, Osta W, Day TA, Jiang JC, Jazwinski SM,
Hannun YA, Obeid LM and Ogretmen B: Defects in cell growth
regulation by C18:0-ceramide and longevity assurance gene 1 in
human head and neck squamous cell carcinomas. J Biol Chem.
279:44311–44319. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Senkal CE, Ponnusamy S, Bielawski J,
Hannun YA and Ogretmen B: Antiapoptotic roles of
ceramide-synthase-6-generated C16-ceramide via selective regulation
of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J.
24:296–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Mayer LD and Janoff AS: Optimizing
combination chemotherapy by controlling drug ratios. Mol Interv.
7:216–223. 2007. View Article : Google Scholar : PubMed/NCBI
|
